BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 85 filers reported holding BIOXCEL THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $759 | -94.7% | 300 | -86.2% | 0.00% | – |
| Q2 2023 | $14,436 | -56.4% | 2,169 | +22.2% | 0.00% | – |
| Q1 2023 | $33,112 | -40.9% | 1,775 | -32.0% | 0.00% | – |
| Q4 2022 | $56,000 | +64.7% | 2,611 | -8.2% | 0.00% | – |
| Q3 2022 | $34,000 | -27.7% | 2,844 | -18.8% | 0.00% | – |
| Q2 2022 | $47,000 | -50.0% | 3,502 | -10.0% | 0.00% | – |
| Q1 2022 | $94,000 | +34.3% | 3,890 | +13.2% | 0.00% | – |
| Q4 2021 | $70,000 | -84.9% | 3,437 | -77.6% | 0.00% | -100.0% |
| Q3 2021 | $465,000 | +14.5% | 15,322 | +9.6% | 0.00% | 0.0% |
| Q2 2021 | $406,000 | -5.1% | 13,985 | +41.2% | 0.00% | 0.0% |
| Q1 2021 | $428,000 | +107.8% | 9,901 | +122.1% | 0.00% | 0.0% |
| Q4 2020 | $206,000 | +35.5% | 4,458 | +28.9% | 0.00% | – |
| Q3 2020 | $152,000 | +94.9% | 3,458 | +134.8% | 0.00% | – |
| Q2 2020 | $78,000 | +100.0% | 1,473 | -19.2% | 0.00% | – |
| Q1 2020 | $39,000 | – | 1,823 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Logos Global Management LP | 430,000 | $19,866,000 | 1.70% |
| APIS CAPITAL ADVISORS, LLC | 20,000 | $924,000 | 0.89% |
| Avidity Partners Management LP | 547,000 | $25,271,000 | 0.82% |
| Knoll Capital Management, LLC | 20,000 | $924,000 | 0.63% |
| Artemis Investment Management LLP | 1,013,448 | $46,839,000 | 0.49% |
| AlphaCentric Advisors LLC | 25,000 | $1,155,000 | 0.48% |
| First Light Asset Management, LLC | 94,202 | $4,352,000 | 0.32% |
| Ikarian Capital, LLC | 150,000 | $6,930,000 | 0.31% |
| Longitude (Cayman) Ltd. | 8,000 | $370,000 | 0.18% |
| AllSquare Wealth Management LLC | 5,490 | $254,000 | 0.17% |